

# 1 Bridging Hemodynamics, Tissue Mechanics, and Pathophysiology in Coronary Artery 2 Disease: A New Agent-Based Model with Tetrahedral Mesh Integration

3  
4 Jeremy Warren<sup>1</sup>, Anna Corti<sup>2</sup>, Clark A. Meyer<sup>1</sup>, Heather N. Hayenga<sup>1\*</sup>

5 <sup>1</sup>Department of Bioengineering, University of Texas at Dallas, Richardson TX 75080, USA

6 <sup>2</sup>Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy

## 7 Abstract

8 We introduce a new multi-physics, multi-scale modeling approach to understand plaque progression  
9 during coronary artery disease. Prior works have coupled agent-based models (ABMs) with finite element  
10 analysis (FEA) or computational fluid dynamics (CFD) to study the individual contributions of tissue  
11 mechanics or hemodynamics to plaque growth. However, these approaches could not simultaneously  
12 capture the dynamic interplay between all three domains that drive plaque development. This study aims  
13 to present a novel method that merges hemodynamics via CFD, biological processes via ABM, and  
14 biomechanics via FEA into a single multi-scale, multi-physics simulation (CAFe). A description of the  
15 mechanisms and modeling approaches utilized in the CAFe model is provided, as well as preliminary  
16 exploration of the model's capabilities in idealized healthy and stenosed coronary artery models. A  
17 volumetric 3D tetrahedral mesh of the artery is shared between CFD, ABM, and FEA to simulate  
18 geometrical and biological changes with continuity and consistency. The CFD and FEA modules,  
19 implemented with FEBio, calculate the wall shear stress and structural stress and strain, respectively. These  
20 biomechanical values are passed to the ABM, implemented in MATLAB, which simulates vascular  
21 remodeling using molecular diffusion, cell migration, equations for cellular processes, and volumetric

22 growth to update the geometry. Initial results using CAFe suggest atherosclerotic arteries seek to maintain  
23 a hemodynamic threshold through preferential growth and remodeling downstream of a stenosis. The  
24 innovative approach described herein marks a significant step forward in predictive modeling of CAD  
25 progression and paves the way for powerful coupling of the spatiotemporal-dependent remodeling  
26 paradigms exhibited by the disease.

27

28 **Keywords:** Coronary Artery Disease (CAD), Computational Modeling, Cardiovascular, Finite Element  
29 Analysis (FEA), Agent Based Modeling (ABM), Biomechanics, FEBio

30

31 \*Address correspondence to:

32 Dr. Heather N. Hayenga

33 The University of Texas at Dallas

34 800 W. Campbell Road, Richardson, TX 75080

35 Phone: 972-883-3558

36 E-mail: [heather.hayenga@utdallas.edu](mailto:heather.hayenga@utdallas.edu)

37

## 38 1. Introduction


39 Coronary artery disease (CAD) is a major cardiovascular disease (CVD); it was responsible for 382,820  
40 deaths in 2020 in the USA, accounting for approximately 55% of all CVD-related deaths that year (Tsao et  
41 al. 2022). CAD is characterized by a buildup of fatty plaque and dead cells inside coronary arteries. Also  
42 called atherosclerosis, CAD obstructs the flow of oxygenated blood, often leading to major adverse  
43 cardiovascular events (e.g., myocardial infarction). An estimated 7.2% of adults in the United States over  
44 the age of 20 have some form of CAD, rising to over 35% for adults over the age of 30 (Blewett et al. 2021).  
45 Given the prevalence and severity of CAD, understanding the biomechanical and structural factors driving  
46 plaque progression and instability is essential for advancing diagnostic and therapeutic approaches.

47 Coronary arteries are constantly responding to changes in biochemical, mechanical, and hemodynamical  
48 loads to maintain homeostatic equilibrium. In CAD, dysfunction in this highly interconnected system is  
49 responsible for plaque deposition and adaptive arterial remodeling. An improved understanding of the  
50 underlying pathological mechanisms of CAD will enable a more accurate prediction of plaque growth and  
51 subsequent management of the prevalent disease.

52 Multiscale agent-based modeling (ABM) has offered valuable insights into the complex interplay of events  
53 that drive the progression of CAD. Previously, computational fluid dynamics (CFD) models have been  
54 coupled with ABMs to understand mechanisms such as hemodynamically driven leukocyte  
55 transendothelial migration (Bhui and Hayenga 2017), the impact of pulsatile flow on leukocyte capture  
56 (Ciri et al. 2018), and plaque growth (Corti et al. 2019; 2020). Separately, a finite element analysis (FEA)  
57 model has been coupled with ABM to investigate the biomechanical mechanisms contributing to arterial  
58 growth and remodeling (Keshavarzian, Meyer, and Hayenga 2018). Both implementations (CFD with ABM  
59 and FEA with ABM) provided a path for more advanced models capable of studying CAD outcomes such  
60 as vascular adaptation (Corti et al. 2021) or restenosis (Corti et al. 2022). However, a fully coupled model

61 that incorporates CFD, ABM, and FEA would allow for a deeper understanding of artery remodeling, as  
62 was recently demonstrated with femoral artery restenosis (Corti et al. 2024).

63 Herein we present CAFe (CFD, ABM, and FEA), a multi-scale, multi-physics, modeling framework of  
64 atherosclerotic plaque growth that is capable of seamlessly coupling all three domains: (i) a CFD module  
65 for hemodynamics, (ii) an ABM module for biological processes, and (iii) a FEA module for structural  
66 mechanics [Figure 1].



67  
68 *Figure 1. Overview of the interconnected submodules of the multi-scale, multi-physics CAFe model. Stresses and strains calculated*  
69 *in the FEA module and wall shear stress (WSS) values from the CFD module drive the biological interactions of the ABM.*

70 This framework introduces a substantial novelty in the coupling mechanism of the three modules by  
71 utilizing a volumetric 3D mesh capable of capturing the geometrical changes produced by plaque growth.  
72 As proof of concept, the CAFe model described herein was applied to two cases of idealized (with respect  
73 to 3D shape and composition) human coronary arteries (Section 2.2). The first case, a non-atherosclerotic  
74 human coronary artery is modeled as a straight axisymmetric cylindrical tube with healthy physiological  
75 inputs to explore the model's response to healthy, homeostatic conditions. In the second case, an

76 atherosclerotic human coronary artery is modeled as a non-axisymmetric tube with a mild 30% stenotic  
77 plaque (Cury et al. 2016). Both cases simulated a timeframe of 6 months, a clinically relevant endpoint  
78 based on the Atorvastatin and PREMIER trials (Svetkey et al. 2003; Eshtehardi et al. 2012), to observe intra-  
79 plaque remodeling while enabling rapid model development.

## 80 2. Methods


### 81 *2.1 A multi-scale, multi-physics framework*

82 CAFE is a multi-scale, multi-physics framework that enables exploration into the underlying mechanisms  
83 contributing to plaque growth by coupling three separate, yet interconnected modules: (i) The ABM  
84 module (Section 2.3) simulates biological processes driving tissue remodeling at the cellular/tissue scale,  
85 (ii) the FEA module (Section 2.4) calculates mechanical stresses and strains from updated composition and  
86 shape, and (iii) the CFD module (Section 2.5) calculates hemodynamical wall shear stress (WSS) reflective  
87 of changes in the luminal geometry.

88 The initial geometry, mesh (nodes and elements), and configuration of each patch (e.g., number of cells,  
89 extracellular matrix (ECM) composition, and molecular concentration), are directly given as inputs or  
90 calculated from ABM rules. Initially, the average edge length of the patches (i.e. elements) is approximately  
91 0.25mm, yet the size of a patch changes during active remodeling. The initial states of stress, strain, and  
92 WSS are calculated by independently executing FEA and CFD simulations using the open-source FEBio  
93 software (Maas et al. 2012).

94 At the end of each ABM time step, the change in volume of each patch is calculated. This change in volume  
95 is used to update the mesh via the volumetric growth submodule (Section 2.3.4). Every 15 ABM timesteps,  
96 the FEA and CFD modules are executed separately to update the mechanical and hemodynamical values,

97 respectively, which are then passed back to the ABM for the next CAFe time step. At the end of each CAFe  
 98 time step, the composition of each patch is updated [Figure 2].




99  
 100 *Figure 2. General flowchart of the CAFe model. After initialization, the ABM updates the geometry via cellular migration, molecular*  
 101 *diffusion, growth and remodeling submodules. Modular CFD and FEA simulations update hemodynamical and mechanical values,*  
 102 *respectively.*

103 **2.2 Coronary artery meshes and compositions**

104 As a proof-of-concept, two idealized human coronary artery geometries are presented. The first case  
 105 represents a segment of a healthy human coronary artery, whereas the second case represents a stenotic  
 106 coronary artery with a 30% stenosis [Figure 3]. Both meshes were comprised of tetrahedral elements with  
 107 an average edge length of 0.25 mm. Case 1 had 75,667 elements and 15,334 nodes, and Case 2 had 76,095  
 108 elements and 15,391 nodes. The number of elements and nodes did not change during the simulation. In

109 both cases, the region of the artery being simulated had an axial length of 8 mm, maximum lumen  
 110 diameter of 3 mm, and radial intimal/medial and adventitial layer thickness of 0.5 mm each (Gradus-Pizlo  
 111 and Feigenbaum 2003; Konishi et al. 2023). The plaque in the stenotic mesh was 3 mm in axial length, 1.5  
 112 mm at the thickest radial point, and 1.5 mm wide circumferentially. In both cases, the region of the artery  
 113 being simulated was encapsulated by a sleeve portion that acts as a surrogate for the connective and  
 114 perivascular tissues in a real coronary artery and the sleeve isolates the region of interest from boundary  
 115 conditions during the volumetric growth and mechanical analyses. A similar approach was utilized in  
 116 silico mechanical simulations of patient-specific arteries (Warren et al. 2022; Guvenir Torun et al. 2021).  
 117 This sleeve layer had a radial thickness of 0.25 mm and an additional axial length of 0.5 mm anterior and  
 118 posterior to the region of interest.



119  
 120 *Figure 3. Idealized meshes of healthy (Case 1) and atherosclerotic (Case 2) human coronary arteries. The intimal/medial layer,*  
 121 *adventitia, and sleeve layers are approximately 0.5, 0.5, and 0.25 mm thick, respectively. Each tetrahedral element (i.e. patch) has*  
 122 *an initial edge length of approximately 0.25mm and contains cell agents, ECM and molecular components. Patches that line the*  
 123 *lumen with an entire face are considered intimal patches and contain ECs determined by the surface area of the lumen face.*

124 The initial quantities of cell agents and ECM constituents within each patch are given as inputs to the CAFe  
 125 model [Table 1]. The initial number of cells in a patch was calculated by multiplying the percent

126 composition of the corresponding tissue type by the volume of the patch and dividing by the cell's volume  
 127 [Table 2]. The initial composition of ECM in each patch was determined similarly, using the mass of ECM  
 128 constituents. Molecular concentrations within a patch are calculated when CAFE initializes using the ABM  
 129 rules. Patches in the intimal and medial layers have vascular smooth muscle cells (VSMCs) and ECM  
 130 components. Those patches facing the luminal surface also contain endothelial cells (ECs), proportional to  
 131 the area of the lumen-adjacent face [Figure 3]. Patches in the adventitial layer contain fibroblasts (FBs)  
 132 and ECM. The plaque patches contain VSMCs and leukocytes. The sleeve layer is empty of cells and does  
 133 not remodel within the ABM, but, as a connective tissue surrogate, contributes mechanically during FEA  
 134 simulations. Other parameters considered in the model are blood LDL content ( $9.5e5 \text{ pg/mm}^3$  for healthy,  
 135  $1.2e6 \text{ pg/mm}^3$  for stenosed (Expert Panel on Detection 2001)) and blood leukocyte density ( $11e3$   
 136  $\text{cells/mm}^3$  (Blumenreich 1990), 50% neutrophils, 30% lymphocytes, and 10% monocytes).

		Plaque (Liu et al. 2011; Villiger et al. 2018)	Artery Wall (Keshavarzian et al. 2018; Wagenseil and Mecham 2009)		
			Intima	Media	Adventitia
Artery Wall Cells	EC	-	Area dependent	-	-
	VSMC	35%	50%*	25%	-
	FB	-	-	-	25%
Leukocytes	Foam cell	15%	-	-	-
	Lymphocyte	2.5%	-	-	-
	Neutrophil	5%	-	-	-
	Monocyte	2.5%	-	-	-
	Macrophage	10%	-	-	-
ECM	Collagen	10%	30%*	35%	35%

	<b>Elastin</b>	10%	10%*	35%	35%
	<b>Gelatin</b>	10%	10%*	5%	5%

137 *Table 1. Initial percent volume composition of each element type. \*Actual percentage determined based on the remaining volume*  
138 *available after accounting for the number of ECs in the lumen face for each patch.*

### 139 *2.3 The ABM module*

140 The ABM module is responsible for simulating processes such as cell turnover, cell migration, production  
141 or reduction of molecules and ECM proteins, molecular diffusion, and volumetric growth [Supplemental  
142 Figure 1]. A 6-hour timestep was used. Within the ABM, four submodules are coupled to simulate plaque  
143 remodeling: (i) biological rules, (ii) cellular migration, (iii) molecular diffusion, and (iv) volumetric growth.

#### 144 *2.3.1 The biological rule sub-module, agents, and components*

145 Biological processes are modeled using equation-based rules derived from literature (Bhui and Hayenga  
146 2017; Keshavarzian et al. 2018; Thorne et al. 2011). These processes include cellular proliferation,  
147 production or removal of solutes, ECM remodeling, leukocyte infiltration, and LDL infiltration.

148 Although other types of equations can be utilized, this study uses four types of equations to represent  
149 these processes: (i) polynomial, (ii) sigmoidal, (iii) piecewise continuous, or (iv) probabilistic. First-order  
150 polynomials are used for basal production rates such as the baseline production of matrix  
151 metalloproteinase (MMP) by VSMCs and FBs [Supplemental Table 1, rules 5, 13-15]. Higher-order  
152 polynomials are used for more complicated processes such as monocyte adhesion as a function of WSS or  
153 LDL concentration at the wall [Supplemental Table 1, rules 32, 53]. Sigmoidal equations are used to  
154 implement threshold effects and saturation points, making them suitable for modeling processes such as  
155 leukocyte adhesion as a function of interleukin-1 (IL1) concentration [Supplemental Table 1, rules 31, 38,  
156 44]. Piece-wise continuous rules are used when appropriate to define outputs with varying responsive

157 ranges. For example, neutrophils only adhere to the endothelium when the WSS is lower than 1.2 Pa but  
158 lack the bond strength to maintain contact with the endothelium when WSS is greater than 1.2 Pa  
159 [Supplemental Table 1, rule 46]. For probabilistic rules, a random number generator is used to model  
160 stochastic processes such as cell proliferation [Supplemental Table 1, rules 1, 2, 10, 11]. When an equation  
161 requires a mechanical or hemodynamic input, the value of the corresponding patch is used. For example,  
162 VSMC production of MMP2 as a function of mechanical stress [Supplemental Table 1, rule 6] uses the  
163 effective stress corresponding to the patch the VSMC resides to calculate  $P_{MMP2}^{VSMC}$ . Temporally, the hourly  
164 output of each rule is scaled to match the 6-hour ABM time step by multiplying by 6. The full list of  
165 equations governing the biological processes in the ABM module can be found in Supplemental Table 1  
166 and were adapted from the work of Bhui et. al. (Bhui and Hayenga 2017) and Keshavarzian et. al.  
167 (Keshavarzian et al. 2018).

168 Each cell agent has 4 parameters: migration velocity, mass, volume, and lifespan [Table 2]. To reduce  
169 computation, the location of an agent is not modeled explicitly within a patch. Instead, the location of an  
170 agent is assumed to be at the “center” of a patch. Regarding cell actions via biological rules, all types of  
171 cells, except for macrophages, are modeled as a collection within a patch; the output of equations with  
172 these cell types is calculated using the total number of cells of a type within a patch as input. For example,  
173 the total amount of MMP1 produced by VSMCs in a patch [Supplemental Table 1, rule 5] is calculated by  
174 multiplying the output of the equation for a single VSMC,  $P_{MMP1}^{VSMC}$ , by the total number of VSMCs in the  
175 patch. Conversely, macrophages are modeled and tracked individually, i.e., equations involving  
176 macrophages are calculated as the output of each individual agent, and then summed together to get a  
177 total value for a given patch. This approach accounts for the phenotypical transformation of macrophages  
178 into foam cells once they consume a certain amount of oxLDL [Supplemental Table 1, rule 57, 58]. Apart  
179 from VSMCs and FBs whose lifespan is rule-based, and ECs and foams cells who live indefinitely, cell  
180 turnover as determined by a cell’s lifespan is used to update the total number of cells at each ABM step.

	Cell Agent	Migration Velocity [mm/h]	Mass [g]	Volume [mm <sup>3</sup> ]	Lifespan [h]
Artery Wall Cells	VSMC	Non-migratory	1.31e-6	1.31e-6	Rule-based
	EC	Non-migratory	5.25e-11	1.25e-7	Inf.
	FB	Non-migratory	9e-10	9e-7	Rule-based
Immune Cells	Lymphocyte	0.1	9e-10	9e-7	336
	Neutrophil	0.6 (Moghe, Nelson, and Tranquillo 1995)	9e-10	9e-7	144
	Monocyte	0.1 (Farrell, Daniele, and Lauffenburger 1990)	9e-10	8.18e-6	336
	Macrophage	0.1 (Farrell et al. 1990)	9e-10	8.18e-6	336
	Foam Cell	Non-migratory	9e-10	8.18e-6	Inf.

181 *Table 2. Parameters defined for each cell agent in the ABM.*

182 Molecular components have three parameters, a diffusion coefficient, molar mass, and half-life [Table 3].

183 Molecular components are represented by the sum of their masses in each patch. The biological rules are

184 used to calculate the amount of each molecular component that is produced in a single ABM time step.

185 Concurrently, the amount of a molecular component that is degraded in a single ABM time step is

186 calculated using its half-life. The remaining amount in each patch is then passed to the diffusion sub-

187 module (Section 2.3.3) to update the concentration gradient for the next timestep.

Name	Diffusion Coefficient [mm <sup>2</sup> /h]	Molar Mass [kDa]	Half-Life [h]	Ref
PDGFab	0.108	26.8	2.4	(Gay and Winkles 1991)
IL1	0.108	17.5	2.5	(Hazuda, Lee, and Young 1988)
IL10	0.108	17.5	2.5	(Hazuda et al. 1988)
TNFa	0.108	17.5	2.5	(Hazuda et al. 1988)
TGFβ	0.108	25	2.5	(Hazuda et al. 1988)
LDL	4.4e-2	2930	68	(Mallol et al. 2012)
oxLDL	4.4e-2	2930	68	(Mallol et al. 2012)

Table 3. Parameters defined for each molecule in the ABM.

188

189 Like molecular components, ECM components are represented as the sum of their mass in each patch.  
 190 The production of structural ECM components (i.e., collagen, elastin, and gelatin) is driven by the actions  
 191 of cellular agents [Supplemental Table 1, rules 5-8], whereas their reduction is driven by degradation via  
 192 matrix metalloproteinases [Supplemental Table 1, rules 22-29].

### 193 2.3.2 The cellular migration sub-module

194 Chemotactic migratory patterns of immune cells are modeled in the cell migration submodule. This  
 195 submodule replicates experimental evidence of leukocytes migrating individually toward a source of a  
 196 chemoattractant (Cano, Vargas, and Lavoie 2016; Lu, Um, and Tartakovsky 2021) with a “random walk”  
 197 pattern by incorporating a simplified algorithm adapted from (Rangarajan and Zaman 2008; Zaman et al.

198 2005) [Supplemental Figure 2] that simulates cellular migration over the course of an ABM time step. The  
199 time step discretization is calculated using patch connectivity, distances between patch centroids, and the  
200 migration velocity of a given cell agent. The decisions of each individual cell agent are modeled. Cells have  
201 a higher probability of migrating into an adjacent patch with a higher chemoattractant concentration than  
202 to a patch with a lower chemoattractant concentration. However, if multiple adjacent patches have a  
203 higher chemoattractant concentration than the patch they resided in, a patch is randomly chosen for the  
204 cell to migrate into. Artery wall cells (VSMCs, ECs, and FBs) are not modeled in the migration submodule,  
205 although they could be incorporated in future models.

### 206 *2.3.3 The molecular diffusion sub-module*

207 Molecular diffusion is modeled during each ABM time step. Concentration gradients are calculated using  
208 the molar mass of each molecule and patch volume. Diffusion is simulated using Fick's second law as a  
209 second order parabolic PDE in MATLAB's PDE solver. The concentration gradient is used as the initial  
210 starting concentration and the 6-hour ABM time step is discretized using patch connectivity. To ensure  
211 mass conservation, a zero-flow Neumann boundary condition (Rapp 2017) is enforced at the external  
212 boundary of the artery region of interest. Of note, ECM components are stationary and do not diffuse.

### 213 *2.3.4 The volumetric growth sub-module*

214 In each ABM time step, changes in ECM composition and the number of cells modify the volume of each  
215 patch. The number of nodes and patches or elements does not change during remodeling. The element-  
216 connectivity of the mesh remains the same, only the nodal coordinates are modified. To ensure the  
217 geometric volume of each patch matches the volume calculated by the ABM, the mesh is updated using a  
218 modified version of the "Cell-Growth" plugin in FEBio (Ateshian et al. 2012). After the biological rules,  
219 migration, and diffusion submodules are executed, a subroutine calculates the fold change in volume  
220 throughout the region of interest and writes a material definition for each patch to a FEBio input file. This

221 material definition ties the volume fold-change to the osmotic pressure component of the Cauchy stress  
 222 equation by imposing positive or negative isotropic pressure to make an element grow or shrink. An  
 223 incompressible hyperelastic Neo-Hookean material with a Young's modulus of 10 MPa is assigned to the  
 224 sleeve elements surrounding the region of interest, serving as a mechanical backbone to constrain growth  
 225 and mimic the properties of healthy arterial tissue. The nodes on both ends of the sleeve region are fixed  
 226 and a pressure load is applied on the lumen to distribute the resulting forces.

227 *2.4 The FEA module*

228 Mechanical stresses and strains drive changes in cell and ECM patch composition which modifies the  
 229 mechanical properties of the artery. To dynamically update changes in material properties of the mesh the  
 230 elastic modulus of each patch is computed from the percent composition of cell agents and ECM  
 231 constituents and their associated elastic modulus [Table 4]. This value is used as the Young's modulus of a  
 232 hyper-elastic isotropic Neo-Hookean material model with a Poisson's ratio of 0.48. The nodes on both ends  
 233 of the sleeve are fixed and a ramped systolic pressure load of 120 mmHg is applied to the luminal surface.  
 234 Mechanical analysis is performed with FEBio's built-in implicit solver. Once complete, an automated script  
 235 reads the Cauchy stress and Green-Lagrange strain values and calculates the effective stress [Supplemental  
 236 Table 1, rule 59] and effective strain [Supplemental Table 1, rule 60] of each patch. These effective stress  
 237 and strain values are then passed back to the ABM for the next timestep.

Agent Type		Elastic Modulus [kPa]	Ref.
ECM	Collagen	442.6	(Lu et al. 2004)
	Elastin	100	(Karšaj, Sorić, and Humphrey 2010; Lu et al. 2004)

	Gelatin	2	(Lou and Chirila 1999; Norris and McGraw 1964; Yakimets et al. 2005)
Cells	VSMC	4.3	(Qiu et al. 2010)
	FB	0.5	(Engler et al. 2004)
	EC	1.42	(Stroka and Aranda-Espinoza 2011)
	Neutrophil	1.5	(Lee, Patel, and Park 2011)
	Lymphocyte	0.085	(Bufi et al. 2015)
	Monocyte	0.52	(Bufi et al. 2015)
	Macrophage & Foam cell	1.2	(Bufi et al. 2015; Patel et al. 2012)


238

*Table 4. Elastic modulus values for each agent used in the FEA module.*

239 *2.5 The CFD module*

240 WSS plays a critical role in plaque remodeling (Timmins et al. 2017; Tziotziou et al. 2023) and LDL uptake  
241 (Deng et al. 1995) in CAD. Rigid CFD simulations using FEBio's fluid solver are utilized to calculate WSS  
242 values. To generate the mesh for the fluid cavity, the luminal surface is isolated and extended 5 diameters  
243 (roughly 15mm) at the inlet and outlet to allow fluid flow to fully develop. This extended lumen surface is  
244 used to generate a volumetric mesh comprised of tetrahedral elements (Si 2015) and pentahedral  
245 elements at the luminal boundary [Figure 4A]. Blood is modeled as a homogeneous, incompressible, and  
246 Newtonian fluid, with a viscosity of  $3.5 \times 10^{-3}$  Pa-s and a density of  $1060 \text{ kg/m}^3$ . Parabolic, laminar pulsatile  
247 blood flow, with a cardiac period of 1 second for 3 cycles is applied to the inlet (He and Ku 1996; Nosovitsky  
248 et al. 1997). Since blood flow is naturally pulsatile, WSS changes significantly throughout the cardiac cycle.  
249 Bhui et al. and Ciri et al. found that the total number of leukocytes migrating into the artery wall over the  
250 course of an hour can be replicated using instantaneous WSS at 45% of the cardiac cycle (Ciri et al. 2018;

251 Bhui and Hayenga 2017). To further ensure consistent WSS calculations, three cardiac cycles are simulated  
252 and the average WSS at 45% of each cardiac cycle [Figure 4B] is used.



253  
254 *Figure 4. CFD simulation mesh and fluid velocity at the inlet. A) The luminal surface of the mesh is isolated and extended 15 mm*  
255 *at the inlet and outlet. 10 layers of pentahedral elements line the luminal boundary to accurately capture WSS. B) Pulsatile bulk*  
256 *velocity at the inlet with 45% of the cycle denoted with arrows.*

### 257 3. Results


258 Simulations were conducted to evaluate CAFe's ability to simulate tissue remodeling, modify geometry,  
259 and to test the coupling between CFD, ABM, and FEA. A Windows x64-based PC with 128 GB RAM and 20  
260 CPU cores was utilized. FEA, CFD, and growth models were performed using FEBio v2.3.0. The ABM and its  
261 submodules as well as the automated interfacing functions were executed in MATLAB vR2022b. Two cases  
262 were considered: 1) a healthy artery with no plaque, and 2) an artery with a 30% stenosis.

#### 263 3.1 Comparison between the healthy and stenosed cases

264 Two simulations were run for each case and a two-tailed Student's T-test was performed showing little  
265 run-to-run variability [Figure 5]. The number of patches and nodes remains the same in all instances. On  
266 average, the total number of VSMCs decreased by 7.9% and 5.3% in the healthy and stenosed cases  
267 ( $p=0.0034$ ), respectively [Figure 5A], whereas the total number of fibroblasts increased by 0.53% and 1.5%  
268 in the healthy and stenosed cases ( $p=0.0011$ ), respectively [Figure 5B]. TGF $\beta$  more than doubled in the

269 stenosed case but remained at zero in the healthy case ( $p=0.0498$ ) [Figure 5C]. Within the first 3 days, the  
270 total amount of PDGFab in the stenosed case dropped significantly but increased slightly in the healthy  
271 case with both instances converging to a homeostatic value around  $5.5e6$  pg by day 5 ( $p<0.001$ ) [Figure  
272 5D]. The total volume of the mesh in the region of interest remained the same and decreased by 3.6% in  
273 the healthy and stenotic case ( $p=0.0639$ ), respectively [Figure 5E]. Although the decrease in volume for  
274 the stenotic case was minimal, the final volume of the plaque (patches containing foam cells) was greater  
275 than two times the original volume. Moreover, the plaque extended downstream from its original position  
276 [Figure 5F]. Mechanical stresses in the healthy artery were more uniformly distributed than the stenosed  
277 case [Supplemental Figure 3]. The effective stress in the healthy case ranged from 35-45 kPa whereas the  
278 stenosed case had stresses as low as 5 kPa in the plaque region and stresses as high as 55 kPa in the regions  
279 directly adjacent to the plaque and in the healthy tissue.

Post-print



280

281 *Figure 5. Comparison between healthy and stenosed cases for cellular, molecular, and volumetric changes. The mean (dashed line)*

282 *± max-min range (shadow) of two simulations are presented for the healthy and stenosed case. A) Total number of VSMCs. B) Total*

283 *number of FBs. C) Total amount of TGFβ. D) Total amount of PDGFαβ. E) Total non-plaque volume in the region of interest. F) Total*

284 *plaque volume in the region of interest with mesh overlay of the stenosed case at day 0, 90, and 180; plaque includes any patches*

285 *with foam cells (plaque shown as yellow in mesh view, non-plaque is red).*

### 286 3.2 Leukocyte infiltration in the stenosed case


287 Regions of low WSS (i.e. <1 Pa for monocytes, <0.41Pa for lymphocytes, and <1.2 Pa for neutrophils

288 [Supplemental Table 1, rule 33, 40, 46]) paired with the presence of IL1 and TNFA drive leukocyte

289 infiltration into the artery. Two simulations were run for the stenosed case [Figure 6]. The surface area of

290 the lumen exposed to a WSS less than 1.2 Pa (the maximum WSS at which leukocytes attach to the wall)

291 shrinks as the model runs [Figure 6A]. The total amount of TNF $\alpha$  and IL1 reached a homeostatic value  
 292 around day 15 [Figure 6B]. The total number of lymphocytes and neutrophils increase for the first 35 days  
 293 and then reach a homeostatic value by day 50 [Figure 6C]. Although not clearly shown in the figure,  
 294 monocytes also infiltrate the wall. However, the rate at which monocytes turn into macrophages was less  
 295 than the rate of macrophage to foam cell transition, hence monocytes and macrophages decrease while  
 296 foam cells consistently increase with time. Foam cells do not have a defined lifespan and accumulate as  
 297 the model runs.



298  
 299 *Figure 6. Axial cross-section views of the stenosed mesh at key time points paired with hemodynamically driven cytokine and*  
 300 *leukocyte amounts. The mean (dashed line)  $\pm$  max-min range (shadow) of two simulations are presented for the stenosed case. A)*

301 *The surface area of the lumen with a WSS that is less than the maximum threshold for leukocyte attachment (i.e., 1.2Pa). B)*  
302 *Evolution of representative TNF $\alpha$  and IL1 concentration in the artery with TNF $\alpha$  concentration shown in mesh view. C) Total number*  
303 *of leukocyte agents in the artery with neutrophils shown in the mesh views.*

#### 304 4. Discussion

305 In the context of coronary artery disease (CAD), we presented an integrated multi-scale, multi-physics  
306 framework that offers a transformative approach to understanding the intricate dynamics of plaque  
307 progression. By combining hemodynamics, biomechanics, and cellular biology into a unified framework,  
308 we can simulate the nuanced interactions between fluid, tissue, and biology and build insight into how  
309 plaque changes over time.

310 Our framework demonstrated an integrated approach to better understand the pathophysiological  
311 processes of CAD. For example, our simulations suggest that regions of the artery that exhibit low WSS are  
312 critical zones for plaque growth which is consistent with current literature that point to hemodynamic  
313 forces playing a pivotal role in disease progression (Samady et al. 2011). We also observed enhanced  
314 leukocyte captured downstream of the maximum luminal stenosis in the stenosed case where flow  
315 separation occurred if the WSS was less than 1.2 Pa. The increased number of leukocytes in this region  
316 corresponded with the location of the highest concentration of cytokines which, in turn, corresponded  
317 with increased leukocyte presence. Additionally, more LDL infiltrated in this region of the wall, contributing  
318 to increased differentiation of macrophages into foam cells. Indeed, these results corroborate longitudinal  
319 clinical studies that show preferential plaque growth in the downstream direction (Smedby 1997).

320 Mechanically, our simulations suggest a more homogenous distribution of mechanical stress in the healthy  
321 artery as compared to the plaque of the stenosed case. Consistent with clinical observations, the  
322 dysregulation of structural ECM and the presence of fatty lipids in the plaque correspond with the  
323 reduction in effective stress observed herein (Liu et al. 2011; Villiger et al. 2018). Hemodynamically, the

324 CAFe model produces similar flow profiles and WSS values to established CFD models. Ciri et al. utilized  
325 both custom and commercial CFD software to model an idealized artery with 30% stenosis at 45% of the  
326 cardiac cycle (Ciri et al. 2018). The WSS is  $\sim 22\text{Pa}$  and  $\sim 25\text{Pa}$  at the minimum lumen diameter and both  
327 below  $1.2\text{Pa}$  downstream of the maximum stenosis in (Ciri et al. 2018) and CAFe, respectively.

328 At the tissue-level, our results are within the range of remodeling seen in experimental studies and clinical  
329 observations of atherosclerosis progression. For example, Pelosi et al. studied atherogenesis in porcine  
330 coronary arteries with a high cholesterol diet over the course of 4 months and observed an average  
331 increase of  $1.93\text{ mm}^2$  in cross-sectional area (Pelosi et al. 2014). Our model estimates a  $1.87\text{ mm}^2$  increase  
332 in mean cross-sectional plaque area over a course of 4 months. Additionally, our model estimates plaque  
333 growth rates comparable to a human clinical trial investigating plaque growth while on Atorvastatin  
334 (Timmins et al. 2017). Specifically, plaque area under regions of low ( $<1\text{Pa}$ ) WSS increased by  $0.007\text{ mm}^2$   
335 over 6 months of the trial or  $0.0035\text{ mm}^2$  over the last 4.5 months our simulation. Moreover, high ( $>2.5\text{Pa}$ )  
336 WSS caused plaque regression in both the trail and our model. Thus, our simulated results roughly  
337 corroborate with an experimental porcine model and clinical values of plaque growth at the tissue-level.

338 However, the CAFe framework has limitations. The idealized geometric and Neo-Hookean material  
339 simplifications within the mechanical models, while necessary for computational feasibility, does not  
340 capture all the nuances of the complex human arterial behavior. Although the arterial deformations seen  
341 herein were relatively small, when available for atherosclerotic tissue, utilizing material models that  
342 incorporate fibers, anisotropy, or larger deformations may increase the accuracy of the model. Our model  
343 also incorporates a wide range of physiological processes which are dependent on the initial conditions  
344 and parameters. These values were derived from existing literature and may not fully capture clinical  
345 variability. For example, the initial percent composition of each tissue type had to be determined from  
346 qualitative observations (Liu et al. 2011; Villiger et al. 2018; Wagenseil and Mecham 2009) rather than  
347 experimental findings due to the rarity and variance in values reported across sources in the literature. As

348 another example, for the healthy artery, there was a 7.9% overall decrease in VSMCs with the majority  
349 occurring within the first 10 simulation steps which suggests the initial conditions were not at homeostasis.  
350 After which the number of VSMCs amount stabilizes which is in line with the adaptation phenomenon that  
351 keeps a physiological VSMC/fibroblast ratio, in agreement with the hypothesis that the relative arterial  
352 cell/ECM composition does not undergo extreme changes over time (Corti et al. 2023). Additionally, 6  
353 months is not long enough to observe an increase in stenosis. Indeed, coronary plaques often take years  
354 to produce noticeable changes in size. For example, a longitudinal 2-year study with 95 patients found the  
355 total plaque volume in patients with normal systolic blood pressure increased in volume by just 0-2.2mm<sup>3</sup>  
356 per year (Won et al. 2022). Yet the 6-month duration was chosen to observe intra-plaque remodeling while  
357 enabling rapid model development (as a 6-month simulation took roughly 15 and 27 hrs for non-stenotic  
358 and stenotic cases, respectively).

## 359 5. Conclusion


360 In conclusion, the CAFe model represents a significant step forward in the simulation of CAD progression  
361 and offers a promising tool for advancing our understanding of the disease. This multi-physics, multi-scale  
362 approach allows for a more comprehensive prediction of disease pathways, potentially leading to targeted  
363 interventions that could preempt disease progression in individual patients. Notably, the CAFe model  
364 could replicate real-world conditions within a controlled simulation environment, allowing us to observe  
365 how key factors such WSS and mechanical stress influence plaque development and remodeling. By  
366 continuing to refine this model, we hope to better predict the progression of atherosclerosis, tailor  
367 interventions to individual patients, and ultimately improve outcomes in the treatment of the disease.

## 368 Acknowledgments and Funding

369 The authors would like to thank Dr. Stefano Leonardi of the Mechanical Engineering Department at UT  
370 Dallas for his expertise and help with the development and implementation of the CFD module. The  
371 authors also gratefully acknowledge funding for this work provided by the National Heart, Lung, And Blood  
372 Institute of the National Institutes of Health (1R01HL136776-01A1). The content is solely the responsibility  
373 of the authors and does not necessarily represent the official views of the National Institutes of Health.  
374 AC is funded by the National Plan for NRRP Complementary Investments (PNC, established with the  
375 decree-law 6 May 2021, n. 59, converted by law n. 101 of 2021) in the call for the funding of research  
376 initiatives for technologies and innovative trajectories in the health and care sectors (Directorial Decree n.  
377 931 of 06-06-2022) - project n. PNC0000003 - AdvANced Technologies for Human-centrEd Medicine  
378 (ANTHEM). This work reflects only the authors' views and opinions, neither the Ministry for University and  
379 Research nor the European Commission can be considered responsible for them.


380

381 Supplemental Materials




382

383 *Supplemental Figure 1. Flowchart of the ABM module. Literature-derived equations govern the biological interactions and*  
 384 *processes which modify the cytokine gradient and number of cells in each patch. A PDE solver computes the second order diffusion*  
 385 *equation for each molecular agent and an in-house algorithm is used to simulate cellular migration. Updated values are used to*  
 386 *calculate the new volume of each patch and determine if the mesh needs to be modified via the growth submodule.*



387

388 *Supplemental Figure 2. Migration implementation. Individual neutrophils in patches near the source of the chemoattractant*  
 389 *migrate up the concentration gradient over the course of 6 hours, resulting in a collective migratory pattern.*



390

391

*Supplemental Figure 3. Mechanical effective stress in the healthy and stenosed cases at the beginning, middle, and end of the 6-month period.*

392

393

POST-PRINT

Rule	Behavior	Equation	Ref
1	Probability of VSMC proliferation as a function of PDGFab	$P(VSMC_{prolif}) = m \cdot \left(1 - \exp\left(-\frac{P_{PDGFab}}{b}\right)\right)$ $m = -3.923e-2 \text{ [h}^{-1}\text{]}$ $b = 3818 \left[\frac{\text{pg}}{\text{mL}}\right]$	(Li et al. 2011)
2	Probability of VSMC apoptosis	$P(VSMC_{apop}) = 3.85e-2 \text{ [h}^{-1}\text{]}$	MBC
3	VSMC production of PDGFab as a function of stress	$M_{PDGFab}^{VSMC} \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}}\right] = m \cdot \sigma + b$ $m = 7.98e-8 \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}\cdot\text{kPa}}\right]$ $b = 6.95e-6 \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}}\right]$	(Hsieh and Frangos n.d.; Li, Moore, and Alavi 1995)
4	VSMC production of TGFβ as a function of stress	$P_{TGF\beta}^{VSMC} \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}}\right] = m \cdot \sigma + b$ $m = 2.76e-7 \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}\cdot\text{kPa}}\right]$ $b = -1.72e-5 \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}}\right]$	(Mata-Greenwood et al. 2005; Morishita et al. 1998)
5	VSMC baseline production of MMP1	$P_{MMP1}^{VSMC} \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}}\right] = a \cdot b$ $a = 39.32\% \text{ (percent active)}$ $b = 4.50e-5 \left[\frac{\text{pg}}{\text{Cell}\cdot\text{h}}\right]$	(Karakiulakis et al. 2007; Owens, Rabinovitch, and Schwartz 1981)

6	VSMC production of MMP2 as a function of stress	$P_{MMP2}^{VSMC} \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right] = a \cdot m \cdot \left( \delta + \alpha \cdot \left( 1 - \exp \left( - \left( \frac{\sigma}{k} \right)^n \right) \right) \right)$ $a = 0.3\% \text{ (percent active),}$ $m = 0.1667 \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right] \text{ (maximum rate),}$ $\delta = 0.03, \alpha = 0.52, k = 101.55 \text{ [kPa], } n = 2.84$	(Kim et al. 2009; Okuno et al. 2002)
7	VSMC production of MMP9 as a function of stress	$P_{MMP9}^{VSMC} \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right] = a \cdot m \cdot \left( \delta + \alpha \cdot \left( 1 - \exp \left( - \left( \frac{\sigma}{k} \right)^n \right) \right) \right)$ $a = 0.3\% \text{ (percent active)}$ $m = 3e-4 \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right] \text{ (maximum rate),}$ $\delta = 0.04, \alpha = 0.44, k = 78.87 \text{ [kPa], } n = 2.88$	(Garcia-Lopez et al. 2007; Kim et al. 2009)
8	VSMC production of collagen as a function of TGFβ and PDGFab	$P_{collagen}^{VSMC} \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right] = \begin{cases} m \cdot P_{TGF\beta} + b, & P_{TGF\beta} > 0 \ \& \ P_{PDGFab} > 0 \\ b, & \text{otherwise} \end{cases}$ $m = 19.16 \text{ [Cell}^{-1}\text{h}^{-1}\text{]}$ $b = 14.98e-4 \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right]$	(Absood et al. 2004; Kim et al. 1988; Schlumberger et al. n.d.)
9	EC production of PDGFab as a function of WSS	$P_{PDGFab}^{EC} \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right] = m \cdot \left( \delta + \alpha \cdot \left( 1 - \exp \left( - \left( \frac{WSS}{k} \right)^n \right) \right) \right)$ $m = 0.104 \left[ \frac{\text{pg}}{\text{Cell}\cdot\text{h}} \right] \text{ (maximum rate)}$ $\delta = 0.15, \alpha = 0.84, k = 2.01 \text{ [Pa], } n = 1.24$	(Aromatario et al. 1997; Hsieh, Li, and Frangos 1991)
10	Probability of FIBRO proliferation as a function of PDGFab	$P(FIBRO_{prolif}) = a + m \cdot \left( 1 - \exp \left( - \left( \frac{P_{PDGFab}}{k} \right)^n \right) \right)$ $a = 1.11e-3 \text{ [h}^{-1}\text{]}, m = 9.41e-3 \text{ [h}^{-1}\text{]}, k = 0.26 \text{ [pg], } n = 1.29$	(Wu et al. 2014; D. K. Kim et al. 1999)
11	Probability of FIBRO apoptosis	$P(FIBRO_{apop}) = 0.0105 \text{ [h}^{-1}\text{]}$	MBC

12	FIBRO production of collagen as a function of strain	$P_{collagen}^{FIBRO} \left[ \frac{pg}{Cell \cdot h} \right] = a \cdot (1 + (m \cdot \epsilon^2 + b \cdot \epsilon))$ $a = 9.23e-3 \left[ \frac{pg}{Cell \cdot h} \right]$ $m = 116, b = 0.8$	(Wu et al. 2014; Jenkins et al. 2007)
13	FIBRO baseline production of MMP1	$P_{MMP1}^{FIBRO} \left[ \frac{pg}{Cell \cdot h} \right] = 12.68e-5$	(Karakiulakis et al. 2007; Ethier, H1ckler, and Saunders 1982)
14	FIBRO baseline production of MMP2	$P_{MMP2}^{FIBRO} \left[ \frac{pg}{Cell \cdot h} \right] = 7.65e-6$	(Okuno et al. 2002), MBC
15	FIBRO baseline production of MMP9	$P_{MMP9}^{FIBRO} \left[ \frac{pg}{Cell \cdot h} \right] = 3.1e-7$	(Garcia-Lopez et al. 2007; Ethier, H1ckler, and Saunders 1982), MBC
16	Total PDGF-AB produced	$P_{PDGFab} = P_{PDGFab}^{VSMC} + P_{PDGFab}^{EC}$	-
17	Total TGFβ produced	$P_{TGF\beta} = P_{TGF\beta}^{VSMC}$	-
18	Total MMP1 produced	$P_{MMP1} = P_{MMP1}^{VSMC} + P_{MMP1}^{FIBRO}$	-
19	Total MMP2 produced	$P_{MMP2} = P_{MMP2}^{VSMC} + P_{MMP2}^{FIBRO}$	-
20	Total MMP9 produced	$P_{MMP9} = P_{MMP9}^{VSMC} + P_{MMP9}^{FIBRO}$	-
21	Total collagen produced	$P_{collagen} = P_{collagen}^{VSMC} + P_{collagen}^{FIBRO}$	-

22	Collagen degraded to gelatin as a function of MMP1	$25 \cdot P_{MMP1} \left[ \frac{pg}{h} \right]$	(Howard G Welgus, Jeffrey, and Eisen 1981; H. G. Welgus et al. 1980)
23	Gelatin degradation as a function of MMP2	$410 \cdot P_{MMP2} \left[ \frac{pg}{h} \right]$	(Xia et al. 1996; Lê et al. 1999)
24	Gelatin degradation as a function of MMP9	$135 \cdot P_{MMP9} \left[ \frac{pg}{h} \right]$	(Xia et al. 1996; Murphy et al. 1985)
25	Elastin degradation as a function of MMP2	$2.64 \cdot P_{MMP2} \left[ \frac{pg}{h} \right]$	(Murphy et al. 1985; Xia et al. 1996; Lê et al. 1999)
26	Elastin degradation as a function of MMP9	$0.87 \cdot P_{MMP9} \left[ \frac{pg}{h} \right]$	(Murphy et al. 1985; Xia et al. 1996; Lê et al. 1999)
27	MMP1 degradation	$\frac{P_{MMP1}}{2.8} \left[ \frac{pg}{h} \right]$	MBC
28	MMP2 degradation	$\frac{P_{MMP2}}{2.15} \left[ \frac{pg}{h} \right]$	MBC
29	MMP9 degradation	$\frac{P_{MMP9}}{2.11} \left[ \frac{pg}{h} \right]$	MBC
30	MONO adhesion as a function of TNF $\alpha$	$A_{MONO}^{TNF\alpha} [Cells] = \begin{cases} \frac{1}{180} \cdot \left( 0.8 - 0.68 \cdot \left( 1 - \exp(-0.33 \cdot \log(x)^{-0.56}) \right) \right), & x > 1 \\ \frac{1}{180} \cdot 0.0996 \cdot x, & x \leq 1 \end{cases}$ $x: P_{TNF\alpha} \left[ \frac{U}{mL} \right]$	(Bahra et al. 1998)

31	MONO adhesion as a function of IL1	$A_{MONO}^{IL1}[\text{Cells}] = \frac{1}{600} \cdot (0.14 + 0.8 \cdot (1 - \exp(-0.58 \cdot x^{1.19})))$ $x: P_{IL1} \left[ \frac{\text{U}}{\text{mL}} \right]$	(Bevilacqua et al. 1985)
32	MONO adhesion as a function of WSS	$A_{MONO}^{WSS}[\text{Cells}] = \frac{1}{600} \cdot (-0.3295 \cdot x^3 + 1.4 \cdot x^2 - 1.8 \cdot x + 0.79)$ $x: WSS [\text{Pa}]$	(Gonzales and Wick 1996)
33	Total number of MONO adhered to endothelium as a function of WSS, IL1, and TNF $\alpha$	$A_{MONO}[\text{Cells}] = \begin{cases} \frac{1}{7.5} \cdot (A_{MONO}^{TNF\alpha} + A_{MONO}^{IL1} + A_{MONO}^{WSS}) \cdot t \cdot \rho \cdot V, & x < 1 \\ 0, & x \geq 1 \end{cases}$ $x: WSS [\text{Pa}], \rho: \text{Blood monocyte density} \left[ \frac{\text{Cells}}{\text{mm}^3} \right], V: \text{Volume} [\text{mm}^3], t: 3600 [\text{s}]$	-
34	Number of adhered MONO that undergo TEM as a function of stiffness	$N_{MONO} = \begin{cases} A_{MONO} \cdot (7.8e-3 \cdot x^2 + 0.048 \cdot x + 0.5106), & x < 0 \\ A_{MONO} \cdot 0.95, & x \geq 0 \end{cases}$ $x: \text{stiffness} [\text{kPa}]$	(Hayenga and Aranda-Espinoza 2013)
35	MONO baseline production of TNF $\alpha$	$P_{TNF\alpha}^{MONO} \left[ \frac{\text{U}}{\text{mL} \cdot \text{h} \cdot \text{Cell}} \right] = 6.7e-4$	(Hatanaka et al. 2006)
36	MONO baseline production of IL1	$P_{IL1}^{MONO} \left[ \frac{\text{U}}{\text{mL} \cdot \text{h} \cdot \text{Cell}} \right] = 5.0e-5$	(Hatanaka et al. 2006)
37	LYMPHO adhesion as a function of TNF $\alpha$	$A_{LYMPHO}^{TNF\alpha}[\text{Cells}] = \begin{cases} \frac{1}{180} \cdot (0.8 - 0.68 \cdot (1 - \exp(-0.33 \cdot \log(x)^{-0.56}))), & x > 1 \\ \frac{1}{180} \cdot 0.0996 \cdot x, & x \leq 1 \end{cases}$ $x: P_{TNF\alpha} \left[ \frac{\text{U}}{\text{mL}} \right]$	(Bahra et al. 1998)
38	LYMPHO adhesion as a function of IL1	$A_{LYMPHO}^{IL1}[\text{Cells}] = \frac{1}{900} \cdot (0.1 + 0.19 \cdot (1 - \exp(-28.29 \cdot x^{1.46})))$ $x: P_{IL1} \left[ \frac{\text{U}}{\text{mL}} \right]$	(Breviario et al. 1988)
39	LYMPHO adhesion as a function of WSS	$A_{LYMPHO}^{WSS}[\text{Cells}] = \frac{1}{25} \cdot (-9.93 \cdot x^3 + 11.0 \cdot x^2 - 4.1 \cdot x + 0.55)$ $x: WSS [\text{Pa}]$	(Munn, Melder, and Jain 1994;

			Melder et al. 1995)
40	Total number of LYMPHO adhered to endothelium as a function of WSS, IL1, and TNF $\alpha$	$A_{LYMPHO}[\text{Cells}] = \begin{cases} \frac{1}{7.5} \cdot (A_{LYMPHO}^{TNF\alpha} + A_{LYMPHO}^{IL1} + A_{LYMPHO}^{WSS}) \cdot t \cdot \rho \cdot V, & x < 0.41 \\ 0, & x \geq 0.41 \end{cases}$ $x: WSS[\text{Pa}], \rho: \text{Blood lymphocyte density} \left[ \frac{\text{Cells}}{\text{mm}^3} \right], V: \text{Volume} [\text{mm}^3], t: 3600 [\text{s}]$	-
41	Number of adhered LYMPHO that undergo TEM as a function of stiffness	$N_{LYMPHO} = \begin{cases} A_{LYMPHO} \cdot (7.8e-3 \cdot x^2 + 0.048 \cdot x + 0.5106), & x < 0 \\ A_{LYMPHO} \cdot 0.95, & x \geq 0 \end{cases}$ $x: \text{stiffness}[\text{kPa}]$	(Hayenga and Aranda-Espinoza 2013)
42	LYMPHO baseline production of IL10	$P_{IL10}^{LYMPHO} \left[ \frac{\text{U}}{\text{mL} \cdot \text{h} \cdot \text{Cell}} \right] = 3.75e-5$	(Rafiq et al. 2001)
43	NEUTRO adhesion as a function of TNF $\alpha$	$A_{NEUTRO}^{TNF\alpha}[\text{Cells}] = \begin{cases} \frac{1}{180} \cdot (0.8 - 0.68 \cdot (1 - \exp(-0.33 \cdot \log(x)^{-0.56}))), & x > 1 \\ \frac{1}{180} \cdot 0.0996 \cdot x, & x \leq 1 \end{cases}$ $x: P_{TNF\alpha} \left[ \frac{\text{U}}{\text{mL}} \right]$	(Bahra et al. 1998)
44	NEUTRO adhesion as a function of IL1	$A_{NEUTRO}^{IL1}[\text{Cells}] = \frac{1}{900} \cdot (0.1 + 0.19 \cdot (1 - \exp(-28.29 \cdot x^{1.46})))$ $x: P_{IL1} \left[ \frac{\text{U}}{\text{mL}} \right]$	(Breviario et al. 1988)
45	NEUTRO adhesion as a function of WSS	$A_{NEUTRO}^{WSS}[\text{Cells}] = \frac{1}{300} \cdot (0.26 \cdot x^2 - 0.8 \cdot x + 0.63)$ $x: WSS[\text{Pa}]$	(Sheikh et al. 2003)
46	Total number of NEUTRO adhered to endothelium as a function of WSS, IL1, and TNF $\alpha$	$A_{NEUTRO}[\text{Cells}] = \begin{cases} \frac{1}{7.5} \cdot (A_{NEUTRO}^{TNF\alpha} + A_{NEUTRO}^{IL1} + A_{NEUTRO}^{WSS}) \cdot t \cdot \rho \cdot V, & x < 1.2 \\ 0, & x \geq 1.2 \end{cases}$ $x: WSS[\text{Pa}], \rho: \text{Blood neutrophil density} \left[ \frac{\text{Cells}}{\text{mm}^3} \right], V: \text{Volume} [\text{mm}^3], t: 3600 [\text{s}]$	-

47	Number of adhered NEUTRO that undergo TEM as a function of stiffness	$N_{NEUTRO} = \begin{cases} A_{NEUTRO} \cdot (9.18e-2 \cdot x + 0.456), & x < 5 \\ A_{NEUTRO} \cdot 0.91, & x \geq 5 \end{cases}$ <p>x: stiffness[kPa]</p>	(Stroka and Aranda-Espinoza 2011)
48	NEUTRO baseline production of TNF $\alpha$	$P_{TNF\alpha}^{NEUTRO} \left[ \frac{U}{mL \cdot h \cdot Cell} \right] = 5.0e-6$	(Hatanaka et al. 2006)
49	NEUTRO baseline production of IL1	$P_{IL1}^{NEUTRO} \left[ \frac{U}{mL \cdot h \cdot Cell} \right] = 5.0e-7$	(Hatanaka et al. 2006)
50	Total TNF- $\alpha$ produced	$P_{TNF\alpha} \left[ \frac{U}{mL \cdot h \cdot Cell} \right] = P_{TNF\alpha}^{MONO} + P_{TNF\alpha}^{NEUTRO}$	-
51	Total IL1 produced	$P_{IL1} \left[ \frac{U}{mL \cdot h \cdot Cell} \right] = P_{IL1}^{MONO} + P_{IL1}^{NEUTRO}$	-
52	Total IL10 produced	$P_{IL10} \left[ \frac{U}{mL \cdot h \cdot Cell} \right] = P_{IL10}^{LYMPHO}$	-
53	Concentration of LDL at endothelium as a function of WSS	$C_{LDL} \left[ \frac{pg}{mm^3} \right] = \begin{cases} C_0 \cdot (2e-8 \cdot x^6 - 2e-6 \cdot x^5 + 6e-5 \cdot x^4 - 1.1e-3 \cdot x^3 + 1.04e-2x^2 - 0.05x + 0.096), & x < 5 \\ 0, & x \geq 5 \end{cases}$ <p>x: WSS [Pa], <math>C_0</math>: Blood LDL concentration <math>\left[ \frac{pg}{Lmm^3} \right]</math></p>	(Deng et al. 1995)
54	LDL infiltration into wall	$P_{LDL} \left[ \frac{pg}{mm^3} \right] = 0.7 \cdot C_{LDL}$ <p>70% of LDL at the lumen</p>	(Deng et al. 1995)
55	LDL oxidation rate	$C_{oxLDL} \left[ \frac{pg}{mm^3} \right] = 0.012 \cdot P_{LDL}$ <p>1.2% per hour</p>	(Pappalardo, Musumeci, and Motta 2008)
56	MONO to MACRO ratio	$N_{MACRO} = \frac{1}{2} \cdot N_{MONO}$ <p>Upon entering the wall, monocytes differentiate into macrophages</p>	(Adamson and Leitinger 2011; Colin, Chinetti-Gbaguidi, and

			Staels 2014; Ley, Miller, and Hedrick 2011; Kadl et al. 2010)
57	MACRO LDL consumption	16.67 $\left[\frac{\text{pg}}{\text{h}}\right]$	(Leake and Rankin 1990)
58	MACRO to FOAM transition	If a macrophage consumes >500 pg LDL, it turns into a foam cell	(Dubland and Francis 2015)
59	Effective (von-Mises) stress	$\sigma = \sqrt{0.5 \cdot \left( (s_x - s_y)^2 + (s_y - s_z)^2 + (s_x - s_z)^2 + 6 \cdot (s_{xy}^2 + s_{yz}^2 + s_{xz}^2) \right)}$ <p> <math>s_x</math>: xx-component of Cauchy stress  <math>s_y</math>: yy-component of Cauchy stress  <math>s_z</math>: zz-component of Cauchy stress  <math>s_{xy}</math>: xy-component of Cauchy stress  <math>s_{yz}</math>: yz-component of Cauchy stress  <math>s_{xz}</math>: xz-component of Cauchy stress </p>	-
60	Effective (Green-Lagrange) strain	$\epsilon = \sqrt{E_x^2 + E_y^2 + E_z^2 - E_{xy} \cdot E_{xz} - E_{xy} \cdot E_{yz} - E_{yz} \cdot E_{xz} + 3 \cdot (E_{xy}^2 + E_{xz}^2 + E_{yz}^2)}$ <p> <math>E_x</math>: xx-component of Green-Lagrange strain  <math>E_y</math>: yy-component of Green-Lagrange strain  <math>E_z</math>: zz-component of Green-Lagrange strain  <math>E_{xy}</math>: xy-component of Green-Lagrange strain  <math>E_{yz}</math>: yz-component of Green-Lagrange strain  <math>E_{xz}</math>: xz-component of Green-Lagrange strain </p>	-

394

Supplemental Table 1. ABM Rules.

395

396 References

- 397 Ateshian, Gerard A, Barclay Morrison, Jeffrey W Holmes, and Clark T Hung. 2012. 'Mechanics of Cell  
398 Growth.' *Mechanics Research Communications* 42 (June):118–25.  
399 <https://doi.org/10.1016/j.mechrescom.2012.01.010>.
- 400 Bhui, Rita, and Heather N. Hayenga. 2017. 'An Agent-Based Model of Leukocyte Transendothelial Migration  
401 during Atherogenesis'. *PLoS Computational Biology* 13 (5).  
402 <https://doi.org/10.1371/journal.pcbi.1005523>.
- 403 Blewett, Lynn A., Julia A. Rivera Drew, Risa Griffin, Natalie Del Ponte, and Pat Convey. 2021. 'Medical  
404 Expenditure Panel Survey, Version 2.1'. <https://Meps.Ipums.Org>. Minneapolis, MN: IPUMS.
- 405 Blumenreich, Martin S. 1990. *The White Blood Cell and Differential Count*.
- 406 Bufi, Nathalie, Michael Saitakis, Stéphanie Dogniaux, Oscar Buschinger, Armelle Bohineust, Alain Richert,  
407 Mathieu Maurin, Claire Hivroz, and Atef Asnacios. 2015. 'Human Primary Immune Cells Exhibit  
408 Distinct Mechanical Properties That Are Modified by Inflammation'. *Biophysical Journal* 108 (9):  
409 2181–90. <https://doi.org/10.1016/j.bpj.2015.03.047>.
- 410 Cano, Patricia M., Amandine Vargas, and Jean-Pierre Lavoie. 2016. 'A Real-Time Assay for Neutrophil  
411 Chemotaxis'. *BioTechniques* 60 (5): 245–51. <https://doi.org/10.2144/000114416>.
- 412 Ciri, Umberto, Rita Bhui, Jorge Bailon-Cuba, Heather N. Hayenga, and Stefano Leonardi. 2018.  
413 'Dependence of Leukocyte Capture on Instantaneous Pulsatile Flow'. *Journal of Biomechanics* 76  
414 (July):84–93. <https://doi.org/10.1016/j.jbiomech.2018.05.044>.
- 415 Corti, Anna, Stefano Casarin, Claudio Chiastra, Monika Colombo, Francesco Migliavacca, and Marc Garbey.  
416 2019. 'A Multiscale Model of Atherosclerotic Plaque Development: Toward a Coupling Between an  
417 Agent-Based Model and CFD Simulations'. In , 410–23. [https://doi.org/10.1007/978-3-030-22747-  
418 0\\_31](https://doi.org/10.1007/978-3-030-22747-0_31).
- 419 Corti, Anna, Claudio Chiastra, Monika Colombo, Marc Garbey, Francesco Migliavacca, and Stefano Casarin.  
420 2020. 'A Fully Coupled Computational Fluid Dynamics – Agent-Based Model of Atherosclerotic Plaque  
421 Development: Multiscale Modeling Framework and Parameter Sensitivity Analysis'. *Computers in  
422 Biology and Medicine* 118 (March):103623. <https://doi.org/10.1016/j.combiomed.2020.103623>.
- 423 Corti, Anna, Monika Colombo, Francesco Migliavacca, Scott A. Berceci, Stefano Casarin, Jose F. Rodriguez  
424 Matas, and Claudio Chiastra. 2022. 'Multiscale Agent-Based Modeling of Restenosis after  
425 Percutaneous Transluminal Angioplasty: Effects of Tissue Damage and Hemodynamics on Cellular  
426 Activity'. *Computers in Biology and Medicine* 147 (August):105753.  
427 <https://doi.org/10.1016/j.combiomed.2022.105753>.
- 428 Corti, Anna, Monika Colombo, Francesco Migliavacca, Jose Felix Rodriguez Matas, Stefano Casarin, and  
429 Claudio Chiastra. 2021. 'Multiscale Computational Modeling of Vascular Adaptation: A Systems  
430 Biology Approach Using Agent-Based Models'. *Frontiers in Bioengineering and Biotechnology* 9  
431 (November). <https://doi.org/10.3389/fbioe.2021.744560>.
- 432 Corti, Anna, Matilde Marradi, Cemre Çelikbudak Orhon, Francesca Boccafoschi, Philippe Büchler, Jose F.  
433 Rodriguez Matas, and Claudio Chiastra. 2024. 'Impact of Tissue Damage and Hemodynamics on  
434 Restenosis Following Percutaneous Transluminal Angioplasty: A Patient-Specific Multiscale Model'.  
435 *Annals of Biomedical Engineering* 52 (8): 2203–20. <https://doi.org/10.1007/s10439-024-03520-1>.

- 436 Corti, Anna, Francesco Migliavacca, Scott A. Berceci, and Claudio Chiastra. 2023. 'Predicting 1-Year in-Stent  
437 Restenosis in Superficial Femoral Arteries through Multiscale Computational Modelling'. *Journal of*  
438 *The Royal Society Interface* 20 (201). <https://doi.org/10.1098/rsif.2022.0876>.
- 439 Cury, Ricardo C., Suhny Abbara, Stephan Achenbach, Arthur Agatston, Daniel S. Berman, Matthew J.  
440 Budoff, Karin E. Dill, et al. 2016. 'CAD-RADSTM Coronary Artery Disease – Reporting and Data System.  
441 An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT), the  
442 American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging  
443 (NASCI). Endorsed by the American College of Cardiology'. *Journal of Cardiovascular Computed*  
444 *Tomography* 10 (4): 269–81. <https://doi.org/10.1016/j.jcct.2016.04.005>.
- 445 Deng, Xiaoyan, Yves Marois, Yahye Merhi, Martin King, R O B E R T Guidoin, and Robert Guidoin. 1995.  
446 'Luminal Surface Concentration of Lipoprotein (LDL) and Its Effect on the Wall Uptake of Cholesterol  
447 by Canine Carotid Arteries'.
- 448 Engler, Adam J., Maureen A. Griffin, Shamik Sen, Carsten G. Bönnemann, H. Lee Sweeney, and Dennis E.  
449 Discher. 2004. 'Myotubes Differentiate Optimally on Substrates with Tissue-like Stiffness'. *Journal of*  
450 *Cell Biology* 166 (6): 877–87. <https://doi.org/10.1083/jcb.200405004>.
- 451 Eshtehardi, Parham, Michael C McDaniel, Saurabh S Dhawan, José Nilo G Binongo, Sandeep K Krishnan,  
452 Lucas Golub, Michel T Corban, Paolo Raggi, Arshed A Quyyumi, and Habib Samady. 2012. 'Effect of  
453 Intensive Atorvastatin Therapy on Coronary Atherosclerosis Progression, Composition, Arterial  
454 Remodeling, and Microvascular Function.' *The Journal of Invasive Cardiology* 24 (10): 522–29.
- 455 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. 'Executive  
456 Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on  
457 Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)'.  
458 *JAMA: The Journal of the American Medical Association* 285 (19): 2486–97.  
459 <https://doi.org/10.1001/jama.285.19.2486>.
- 460 Farrell, Brian E., Ronald P. Daniele, and Douglas A. Lauffenburger. 1990. 'Quantitative Relationships  
461 between Single-cell and Cell-population Model Parameters for Chemosensory Migration Responses  
462 of Alveolar Macrophages to C5a'. *Cell Motility* 16 (4): 279–93.  
463 <https://doi.org/10.1002/cm.970160407>.
- 464 Gay, Cyril G., and Jeffrey A. Winkles. 1991. 'The Half-Lives of Platelet-Derived Growth Factor A- and B-Chain  
465 MRNAS Are Similar in Endothelial Cells and Unaffected by Heparin-Binding Growth Factor-1 or  
466 Cycloheximide'. *Journal of Cellular Physiology* 147 (1): 121–27.  
467 <https://doi.org/10.1002/jcp.1041470116>.
- 468 Gradus-Pizlo, Irmira, and Harvey Feigenbaum. 2003. 'Potential Use of High-Resolution Two-Dimensional  
469 Transthoracic Echocardiography for Visualization of the Left Anterior Descending Coronary Artery'.  
470 *The American Heart Hospital Journal* 1 (1): 77–82. <https://doi.org/10.1111/j.1541-9215.2003.02101.x>.
- 472 Guvenir Torun, Su, Hakki M. Torun, Hendrik H. G. Hansen, Giulia Gandini, Irene Berselli, Veronica Codazzi,  
473 Chris L. de Korte, et al. 2021. 'Multicomponent Mechanical Characterization of Atherosclerotic  
474 Human Coronary Arteries: An Experimental and Computational Hybrid Approach'. *Frontiers in*  
475 *Physiology* 12 (September). <https://doi.org/10.3389/fphys.2021.733009>.
- 476 Hazuda, D J, J C Lee, and P R Young. 1988. 'The Kinetics of Interleukin 1 Secretion from Activated  
477 Monocytes. Differences between Interleukin 1 Alpha and Interleukin 1 Beta.' *Journal of Biological*  
478 *Chemistry* 263 (17): 8473–79. [https://doi.org/10.1016/S0021-9258\(18\)68502-3](https://doi.org/10.1016/S0021-9258(18)68502-3).

479 He, Xiaoyi, and David N. Ku. 1996. 'Pulsatile Flow in the Human Left Coronary Artery Bifurcation: Average  
480 Conditions'. *Journal of Biomechanical Engineering* 118 (1): 74–82.  
481 <https://doi.org/10.1115/1.2795948>.

482 Karšaj, I., J. Sorić, and J.D. Humphrey. 2010. 'A 3-D Framework for Arterial Growth and Remodeling in  
483 Response to Altered Hemodynamics'. *International Journal of Engineering Science* 48 (11): 1357–72.  
484 <https://doi.org/10.1016/j.ijengsci.2010.06.033>.

485 Keshavarzian, Maziyar, Clark A. Meyer, and Heather N. Hayenga. 2018. 'Mechanobiological Model of  
486 Arterial Growth and Remodeling'. *Biomechanics and Modeling in Mechanobiology* 17 (1): 87–101.  
487 <https://doi.org/10.1007/s10237-017-0946-y>.

488 Konishi, Takao, Saikat Kumar B. Ghosh, Yu Sato, Rika Kawakami, Kenji Kawai, Aimee E. Vozenilek, Weili Xu,  
489 et al. 2023. 'The Histological Analysis of the Coronary Medial Thickness: Implications for  
490 Percutaneous Coronary Intervention'. *PLOS ONE* 18 (3): e0283840.  
491 <https://doi.org/10.1371/journal.pone.0283840>.

492 Lee, Yong J., Dipika Patel, and Soyeun Park. 2011. 'Local Rheology of Human Neutrophils Investigated Using  
493 Atomic Force Microscopy'. *International Journal of Biological Sciences* 7 (1): 102–11.  
494 <https://doi.org/10.7150/ijbs.7.102>.

495 Liu, Linbo, Joseph A. Gardecki, Seemantini K. Nadkarni, Jimmy D. Toussaint, Yukako Yagi, Brett E. Bouma,  
496 and Guillermo J. Tearney. 2011. 'Imaging the Subcellular Structure of Human Coronary  
497 Atherosclerosis Using Micro-Optical Coherence Tomography'. *Nature Medicine* 17 (8): 1010–14.  
498 <https://doi.org/10.1038/nm.2409>.

499 Lou, Xia, and Traian V. Chirila. 1999. 'Swelling Behavior and Mechanical Properties of Chemically Cross-  
500 Linked Gelatin Gels for Biomedical Use'. *Journal of Biomaterials Applications* 14 (2): 184–91.  
501 <https://doi.org/10.1177/088532829901400204>.

502 Lu, Hannah, Kimoon Um, and Daniel M. Tartakovsky. 2021. 'Hybrid Models of Chemotaxis with Application  
503 to Leukocyte Migration'. *Journal of Mathematical Biology* 82 (4). <https://doi.org/10.1007/s00285-021-01581-7>.

505 Lu, Qijin, Kavitha Ganesan, Dan T. Simionescu, and Narendra R. Vyavahare. 2004. 'Novel Porous Aortic  
506 Elastin and Collagen Scaffolds for Tissue Engineering'. *Biomaterials* 25 (22): 5227–37.  
507 <https://doi.org/10.1016/j.biomaterials.2003.12.019>.

508 Maas, Steve A, Benjamin J Ellis, Gerard A Ateshian, and Jeffrey A Weiss. 2012. 'FEBio: Finite Elements for  
509 Biomechanics'. *Journal of Biomechanical Engineering* 134 (1): 011005.  
510 <https://doi.org/10.1115/1.4005694>.

511 Mallol, Roger, Miguel A. Rodríguez, Mercedes Heras, Maria Vinaixa, Núria Plana, Lluís Masana, Gareth A.  
512 Morris, and Xavier Correig. 2012. 'Particle Size Measurement of Lipoprotein Fractions Using  
513 Diffusion-Ordered NMR Spectroscopy'. *Analytical and Bioanalytical Chemistry* 402 (7): 2407–15.  
514 <https://doi.org/10.1007/s00216-011-5705-9>.

515 Moghe, Prabhas V., Robert D. Nelson, and Robert T. Tranquillo. 1995. 'Cytokine-Stimulated Chemotaxis of  
516 Human Neutrophils in a 3-D Conjoined Fibrin Gel Assay'. *Journal of Immunological Methods* 180 (2):  
517 193–211. [https://doi.org/10.1016/0022-1759\(94\)00314-M](https://doi.org/10.1016/0022-1759(94)00314-M).

518 Norris, T. O., and John McGraw. 1964. 'Gelatin Coatings and Tensile Strength of Gelatin Films'. *Journal of*  
519 *Applied Polymer Science* 8 (5): 2139–45. <https://doi.org/10.1002/app.1964.070080514>.

520 Nosovitsky, Victor A., Olusegun J. Ilegbusi, Joseph Jiang, Peter H. Stone, and Charles L. Feldman. 1997.  
521 'Effects of Curvature and Stenosis-Like Narrowing on Wall Shear Stress in a Coronary Artery Model  
522 with Phasic Flow'. *Computers and Biomedical Research* 30 (1): 61–82.  
523 <https://doi.org/10.1006/cbmr.1997.1434>.

524 Patel, Naimish R., Medhavi Bole, Cheng Chen, Charles C. Hardin, Alvin T. Kho, Justin Mih, Linhong Deng, et  
525 al. 2012. 'Cell Elasticity Determines Macrophage Function'. *PLoS ONE* 7 (9): e41024.  
526 <https://doi.org/10.1371/journal.pone.0041024>.

527 Pelosi, Gualtiero, Silvia Rocchiccioli, Antonella Cecchetti, Federica Viglione, Mariarita Puntoni, Oberdan  
528 Parodi, Enrico Capobianco, and Maria G. Trivella. 2014. 'Inflammation Blood and Tissue Factors of  
529 Plaque Growth in an Experimental Model Evidenced by a Systems Approach'. *Frontiers in Genetics* 5  
530 (April). <https://doi.org/10.3389/fgene.2014.00070>.

531 Qiu, Hongyu, Yi Zhu, Zhe Sun, Jerome P. Trzeciakowski, Meredith Gansner, Christophe Depre, Ranillo R.G.  
532 Resuello, et al. 2010. 'Short Communication: Vascular Smooth Muscle Cell Stiffness As a Mechanism  
533 for Increased Aortic Stiffness With Aging'. *Circulation Research* 107 (5): 615–19.  
534 <https://doi.org/10.1161/CIRCRESAHA.110.221846>.

535 Rangarajan, Rajagopal, and Muhammad H. Zaman. 2008. 'Modeling Cell Migration in 3D'. *Cell Adhesion &*  
536 *Migration* 2 (2): 106–9. <https://doi.org/10.4161/cam.2.2.6211>.

537 Rapp, Bastian E. 2017. 'Engineering Mathematics'. In *Microfluidics: Modelling, Mechanics and*  
538 *Mathematics*, 21–50. Elsevier. <https://doi.org/10.1016/B978-1-4557-3141-1.50003-4>.

539 Samady, Habib, Parham Eshtehardi, Michael C. McDaniel, Jin Suo, Saurabh S. Dhawan, Charles Maynard,  
540 Lucas H. Timmins, Arshed A. Quyyumi, and Don P. Giddens. 2011. 'Coronary Artery Wall Shear Stress  
541 Is Associated With Progression and Transformation of Atherosclerotic Plaque and Arterial  
542 Remodeling in Patients With Coronary Artery Disease'. *Circulation* 124 (7): 779–88.  
543 <https://doi.org/10.1161/CIRCULATIONAHA.111.021824>.

544 Si, Hang. 2015. 'TetGen, a Delaunay-Based Quality Tetrahedral Mesh Generator'. *ACM Transactions on*  
545 *Mathematical Software* 41 (2): 1–36. <https://doi.org/10.1145/2629697>.

546 Smedby, Örjan. 1997. 'Do Plaques Grow Upstream or Downstream?' *Arteriosclerosis, Thrombosis, and*  
547 *Vascular Biology* 17 (5): 912–18. <https://doi.org/10.1161/01.ATV.17.5.912>.

548 Stroka, Kimberly M., and Helim Aranda-Espinoza. 2011. 'Endothelial Cell Substrate Stiffness Influences  
549 Neutrophil Transmigration via Myosin Light Chain Kinase-Dependent Cell Contraction'. *Blood* 118 (6):  
550 1632–40. <https://doi.org/10.1182/blood-2010-11-321125>.

551 Svetkey, Laura P, David W Harsha, William M Vollmer, Victor J Stevens, Eva Obarzanek, Patricia J Elmer,  
552 Pao-Hwa Lin, et al. 2003. 'Premier: A Clinical Trial of Comprehensive Lifestyle Modification for Blood  
553 Pressure Control: Rationale, Design and Baseline Characteristics'. *Annals of Epidemiology* 13 (6): 462–  
554 71. [https://doi.org/10.1016/S1047-2797\(03\)00006-1](https://doi.org/10.1016/S1047-2797(03)00006-1).

555 Thorne, Bryan C., Heather N. Hayenga, Jay D. Humphrey, and Shayn M. Peirce. 2011. 'Toward a Multi-Scale  
556 Computational Model of Arterial Adaptation in Hypertension: Verification of a Multi-Cell Agent-  
557 Based Model'. *Frontiers in Physiology* MAY. <https://doi.org/10.3389/fphys.2011.00020>.

558 Timmins, Lucas H., David S. Molony, Parham Eshtehardi, Michael C. McDaniel, John N. Oshinski, Don P.  
559 Giddens, and Habib Samady. 2017. 'Oscillatory Wall Shear Stress Is a Dominant Flow Characteristic  
560 Affecting Lesion Progression Patterns and Plaque Vulnerability in Patients with Coronary Artery  
561 Disease'. *Journal of the Royal Society Interface* 14 (127). <https://doi.org/10.1098/rsif.2016.0972>.

562 Tsao, Connie W., Aaron W. Aday, Zaid I. Almarzooq, Alvaro Alonso, Andrea Z. Beaton, Marcio S. Bittencourt,  
563 Amelia K. Boehme, et al. 2022. 'Heart Disease and Stroke Statistics—2022 Update: A Report From  
564 the American Heart Association'. *Circulation* 145 (8).  
565 <https://doi.org/10.1161/CIR.0000000000001052>.

566 Tziotziou, Aikaterini, Eline Hartman, Suze-Anne Korteland, Aad van der Lugt, Antonius F.W. van der Steen,  
567 Joost Daemen, Daniel Bos, Jolanda Wentzel, and Ali C. Akyildiz. 2023. 'Mechanical Wall Stress and  
568 Wall Shear Stress Are Associated with Atherosclerosis Development in Non-Calcified Coronary  
569 Segments'. *Atherosclerosis* 387 (December):117387.  
570 <https://doi.org/10.1016/j.atherosclerosis.2023.117387>.

571 Villiger, Martin, Kenichiro Otsuka, Antonios Karanasos, Pallavi Doradla, Jian Ren, Norman Lippok, Milen  
572 Shishkov, et al. 2018. 'Coronary Plaque Microstructure and Composition Modify Optical Polarization:  
573 A New Endogenous Contrast Mechanism for Optical Frequency Domain Imaging'. *JACC:  
574 Cardiovascular Imaging* 11 (11): 1666–76. <https://doi.org/10.1016/j.jcmg.2017.09.023>.

575 Wagenseil, Jessica E., and Robert P. Mecham. 2009. 'Vascular Extracellular Matrix and Arterial Mechanics'.  
576 *Physiological Reviews*. <https://doi.org/10.1152/physrev.00041.2008>.

577 Warren, Jeremy L., John E. Yoo, Clark A. Meyer, David S. Molony, Habib Samady, and Heather N. Hayenga.  
578 2022. 'Automated Finite Element Approach to Generate Anatomical Patient-Specific Biomechanical  
579 Models of Atherosclerotic Arteries from Virtual Histology-Intravascular Ultrasound'. *Frontiers in  
580 Medical Technology* 4 (November). <https://doi.org/10.3389/fmedt.2022.1008540>.

581 Won, Ki-Bum, Hyung-Bok Park, Ran Heo, Byoung Kwon Lee, Fay Y. Lin, Martin Hadamitzky, Yong-Jin Kim, et  
582 al. 2022. 'Longitudinal Quantitative Assessment of Coronary Atherosclerosis Related to Normal  
583 Systolic Blood Pressure Maintenance in the Absence of Established Cardiovascular Disease'. *Clinical  
584 Cardiology* 45 (8): 873–81. <https://doi.org/10.1002/clc.23870>.

585 Yakimets, Iryna, Nikolaus Wellner, Andrew C. Smith, Reginald H. Wilson, Imad Farhat, and John Mitchell.  
586 2005. 'Mechanical Properties with Respect to Water Content of Gelatin Films in Glassy State'. *Polymer*  
587 46 (26): 12577–85. <https://doi.org/10.1016/j.polymer.2005.10.090>.

588 Zaman, Muhammad H., Roger D. Kamm, Paul Matsudaira, and Douglas A. Lauffenburger. 2005.  
589 'Computational Model for Cell Migration in Three-Dimensional Matrices'. *Biophysical Journal* 89 (2):  
590 1389–97. <https://doi.org/10.1529/biophysj.105.060723>.

591